The EGFR Inhibitor Family

## Overview

Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase (RTK) mutated or amplified in many cancers, most notably non-small cell lung cancer (NSCLC), where activating mutations in the EGFR kinase domain (L858R and exon 19 deletions) occur in ~15% of Western and ~50% of East Asian NSCLC patients. EGFR inhibitors have been developed across three generations over 25 years, driven by the recurring problem of drug resistance: each generation was designed to overcome the mechanisms of resistance to its predecessor.

## First Generation: Reversible Quinazolines

Gefitinib (Iressa) and erlotinib (Tarceva) were the first small-molecule EGFR TKIs. Both use a 4-anilino quinazoline scaffold that mimics ATP's adenine ring binding to the EGFR kinase hinge. The quinazoline N1 accepts a hydrogen bond from Met769 backbone NH, while N3 donates to a water molecule coordinating the ATP-binding site. This binding mode is competitive with ATP and reversible. In WT EGFR (normal cells), gefitinib/erlotinib show modest selectivity over other kinases, but EGFR-activating mutations (L858R, exon 19 deletion) pre-organize the kinase into the inhibitor-preferred active conformation, increasing inhibitor affinity ~100-fold while decreasing ATP affinity—a selectivity bonus.

## Resistance via T790M

Despite initial dramatic responses, most patients with EGFR-mutant NSCLC develop resistance after ~10–14 months. The most common mechanism (~60% of resistance) is the secondary T790M mutation in the EGFR gatekeeper position. Thr790→Met790 abolishes the H-bond that gefitinib/erlotinib make with the threonine hydroxyl, and the bulkier methionine side chain creates steric clash. This is analogous to the T315I mutation in BCR-ABL.

## Second Generation: Pan-ERBB Covalent Inhibitors

Afatinib (Gilotrif) and dacomitinib address resistance by forming an irreversible covalent bond with Cys797 of EGFR, using an acrylamide Michael acceptor at C6 of the quinazoline. Being covalent, they are not displaced by ATP and maintain inhibition even in the presence of T790M—in theory. In practice, second-generation inhibitors are insufficiently selective against T790M EGFR (WT EGFR inhibition causes skin and GI toxicity before T790M mutant is adequately suppressed). Afatinib also inhibits HER2 and HER4, which provides additional efficacy in some contexts but adds toxicity.

## Third Generation: Mutant-Selective Osimertinib

Osimertinib (Tagrisso, AZD9291) represents the pinnacle of resistance-guided drug design. Rather than simply adding a covalent warhead, osimertinib replaced the quinazoline scaffold with an indole-pyrimidine core. The pyrimidine still H-bonds with Met769, but the C3-methoxy indole and dimethylindole substituents adopt a geometry that accommodates the Met790 gatekeeper while clashing with the WT Thr790. This achieves ~800-fold selectivity for T790M mutant EGFR over WT EGFR, enabling therapeutic windows not achievable with second-generation TKIs. Osimertinib also inhibits the exon 20 insertion mutations common in some NSCLC populations and is now standard first-line therapy for EGFR-mutant NSCLC, with 18.9-month median progression-free survival.

## C797S: Third-Generation Resistance

Resistance to osimertinib commonly arises through C797S, which removes the cysteine that forms the covalent bond. This mutation does not affect reversible inhibitors—and clinical evidence shows that patients with C797S on a T790M background can respond to first-generation inhibitors. This provides the biological rationale for combination strategies using allosteric EGFR inhibitors (EAI045, targeting the inactive conformation through a non-ATP site) or fourth-generation mutant-selective reversible inhibitors.

## Key Takeaways

- Quinazoline mimics ATP adenine binding at EGFR hinge (Met769); N1/N3 H-bonds define the pharmacophore
- Activating mutations (L858R, del19) increase inhibitor affinity ~100-fold by stabilizing the active conformation
- T790M gatekeeper mutation drives first/second generation resistance; osimertinib's scaffold bypass achieves mutant selectivity
- Covalent warhead (acrylamide/butynamide) to Cys797 provides irreversible inhibition; C797S resistance removes the cysteine
- Third-generation osimertinib is now first-line standard of care, demonstrating that mutation-selective design is clinically superior